|
|
Interactions
with Gamma-Linolenic Acid (GLA) | |
Ceftazidime
The activity of ceftazidime against Pseudomonas aeruginosa appears to be
potentiated by fatty acids, including GLA (Giamarellos-Bourboulis et al. 1999).
In vitro, GLA exerts bacteriostatic effects on Escherichia coli and, in
combination with arachidonic acid, is bacteriocidal to P
aeruginosa. Cisplatin;
Doxorubicin
In ovarian cancer cells, pre-incorporation of either gamma-linolenic acid
(GLA) or eicosapentaenoic acid (EPA) increased sensitivity to doxorubicin and
cisplatin; however, it was difficult to distinguish the cytotoxicity of the drug
from the fatty acid (Plumb et al. 1993). The cytotoxicity of the fatty acids was
additive with that of the drugs. Another study investigating the effectiveness
of this combination therapy on human neuroblastoma cell lines found that
addition of GLA to the growth medium reduced the cytotoxic effects of cisplatin
and carboplatin (Ikushima et al. 1990).
Idarubicin;
Mitoxantrone
Preclinical data suggest a possible enhancement of cellular uptake of
idarubicin when cells are enriched with GLA (Davies et al. 1999). In multidrug
resistant human breast cancer and bladder cancer cells, pre-incorporation of GLA
at non-cytotoxic levels increased the cellular uptake of idarubicin. In
addition, GLA changed the intracellular distribution of
mitoxantrone. Tamoxifen
GLA may interact with the estrogen receptor antagonist tamoxifen. In one
short-term phase II clinical trial, high-dose GLA therapy (8 capsules/day po
supplying 2.8 g GLA) potentiated the effects of tamoxifen (20 mg od) in 38 stage
I-II breast cancer patients, 90% of whom were estrogen receptor-positive (Kenny
et al. 2000). Patients given GLA exhibited a faster treatment response that was
evident by 6 weeks.
Vincristine;
Vinblastine
In human neuroblastoma cell lines, addition of GLA to the growth medium
enhanced the cytotoxic effects of the vinca alkaloids, vincristine, vinblastine,
and vindesine (Ikushima et al. 1990). In both vincristine-sensitive and
-resistant human cervical cancer cells, GLA was cytotoxic (Madhavi and Das
1994). |

|
|
References |
|
Davies CL, Loizidou M, Cooper AJ, et al. Effect of gamma-linolenic acid on
cellular uptake of structurally related anthracyclines in human drug sensitive
and multidrug resistant bladder and breast cancer cell lines. Eur J
Cancer. 1999;35:1534-1540.
Giamarellos-Bourboulis EJ, Grecka P, Dionyssiou-Asteriou A, et al. In vitro
interactions of gamma-linolenic acid and arachidonic acid with ceftazidime on
multiresistant Pseudomonas aeruginosa. Lipids. 1999;34:S151-152.
Ikushima S, Fujiwara F, Todo S, Imashuku S. Gamma linolenic acid alters the
cytotoxic activity of anticancer drugs on cultured human neuroblastoma cells.
Anticancer Res. 1990;10:1055-1059.
Kenny FS, Pinder SE, Ellis IO et al. Gamma linolenic acid with tamoxifen as
primary therapy tn breast cancer. Int J Cancer. 2000;85:643-648.
Madhavi N, Das UN. Effect of n-6 and n-3 fatty acids on the survival of
vincristine sensitive and resistant human cervical carcinoma cells in vitro.
Cancer Lett. 1994;84:31-41.
Plumb JA, Luo W, Kerr DJ. Effect of polyunsaturated fatty acids on the drug
sensitivity of human tumour cell lines resistant to either cisplatin or
doxorubicin. Br J Cancer.
1993;67:728-733. |

|
Copyright © 2000 Integrative Medicine
Communications This publication contains
information relating to general principles
of medical care that should not in any event be construed as specific
instructions for individual patients. The publisher does not accept any
responsibility for the accuracy of the information or the consequences arising
from the application, use, or misuse of any of the information contained herein,
including any injury and/or damage to any person or property as a matter of
product liability, negligence, or otherwise. No warranty, expressed or implied,
is made in regard to the contents of this material. No claims or endorsements
are made for any drugs or compounds currently marketed or in investigative use.
The reader is advised to check product information (including package inserts)
for changes and new information regarding dosage, precautions, warnings,
interactions, and contraindications before administering any drug, herb, or
supplement discussed herein. | |